Additional file 2 of Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Authors
Publication date
29 September 2022
Publisher
Doi

    Abstract

    Additional file 2. Characteristics of Included 136 studies

      Similar works

      Full text

      thumbnail-image

      Available Versions

      FigShare

      redirect
      oaioai:figshare.com:article/21228...
      Last time updated on 04/10/2022